SARS-CoV-2 CD8+ T cell killing assays using replicating viruses and transgenic antigens. Mateyka et al.

Published: 12 August 2022| Version 1 | DOI: 10.17632/zsdbksr7y7.1
Contributor:
Laura Mateyka

Description

Supplementary videos of xCELLigence based target antigen killing assay of the brightfield channel overlayered with the RFP channel (2 images/second, 72h total) can be found online. Uploaded are videos for competent A549-Nsp2 cells as well as of competent A549-Gaussia cells with the addition of SARS-CoV-2-specific, TCR-engineered CD8+ T cells (E:T ratio 3:1, S13 and S32): Movie S1 comp. A549-Nsp2 TCR S13 E_T 3_1, related to section ‘Expected outcomes’; Movie S2 comp. A549-Nsp2 TCR S32 E_T 3_1, related to section ‘Expected outcomes’; Movie S3 comp. A549-Gaussia TCR S13 E_T 3_1, related to section ‘Expected outcomes’; Movie S4 comp. A549-Gaussia TCR S32 E_T 3_1, related to section ‘Expected outcomes’.

Files

Categories

Immunology, Cell Culture, Cytotoxicity Assay, Severe Acute Respiratory Syndrome Coronavirus 2

Licence